Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,299 JPY | -0.39% | +0.61% | -6.77% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.43 for the 2024 fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.77% | 3.05B | C- | ||
-34.16% | 14.83B | B- | ||
-24.55% | 12.04B | B | ||
-25.24% | 6.52B | B | ||
+14.96% | 6.44B | C | ||
-8.01% | 6.15B | C+ | ||
-2.63% | 4.64B | D- | ||
+60.00% | 4.62B | C | ||
-8.10% | 3.93B | B | ||
-11.16% | 3.49B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3141 Stock
- Ratings Welcia Holdings Co., Ltd.